Hyperprogressive Disease in Anorectal Melanoma Treated by PD-1 Inhibitors

The 5-year survival rate of primary anorectal malignant melanoma is less than 20%. Optimal treatment of this condition remains controversial regarding locally disease, and whether any preferential survival benefit arises from either abdominoperineal resection or wide local excision remains unknown....

Descripción completa

Detalles Bibliográficos
Autores principales: Faure, Marjorie, Rochigneux, Philippe, Olive, Daniel, Taix, Sébastien, Brenot-Rossi, Isabelle, Gilabert, Marine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5916968/
https://www.ncbi.nlm.nih.gov/pubmed/29725330
http://dx.doi.org/10.3389/fimmu.2018.00797

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5916968/
https://www.ncbi.nlm.nih.gov/pubmed/29725330
http://dx.doi.org/10.3389/fimmu.2018.00797

Ejemplares similares